PharmiWeb.com - Global Pharma News & Resources
11-Dec-2018

Global Pediatric Epilepsy Therapeutics Market Forecast to 2023: Expected to Register a CAGR of ~6% - ResearchAndMarkets.com

The "Global Pediatric Epilepsy Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.

The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures.

Increasing demand for second and third-generation AEDs

The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate and lamotrigine, as they have low interaction and propensity for cognitive side-effects.

Adverse side effects and increasing social stigma

The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.

Competitive Landscape

With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.

Key Players

  • Eisai
  • GlaxoSmithKline
  • GW Pharmaceuticals
  • Pfizer
  • UCB

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Second-generation anti-epileptics - Market size and forecast 2018-2023
  • Third-generation anti-epileptics - Market size and forecast 2018-2023
  • First-generation anti-epileptics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eisai
  • GlaxoSmithKline
  • GW Pharmaceuticals
  • Pfizer
  • UCB

For more information about this report visit https://www.researchandmarkets.com/research/749tws/global_pediatric?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181211005812/en/

Editor Details

Last Updated: 11-Dec-2018